Ontology highlight
ABSTRACT:
SUBMITTER: Li J
PROVIDER: S-EPMC7027461 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Li Jianke J Holmes Melissa M Kankam Martin M Trone Denise D Mendell Jeanne J Gammon Guy G
Clinical pharmacology in drug development 20200108 2
Quizartinib is an oral, highly potent, and selective type II FMS-like tyrosine kinase 3 inhibitor in development for acute myeloid leukemia. This parallel-group study evaluated potential food effects on quizartinib absorption in healthy subjects who received a single 30-mg dose after overnight fasting (n = 34) or a high-fat, high-calorie meal (n = 30). Blood samples were collected through 504 hours after dosing, and pharmacokinetic parameters calculated were maximum observed concentration (C<sub ...[more]